EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Five-year outcomes of a drug-coated polymer-free biolimus-eluting stent versus an ultrathin-strut biodegradable-polymer sirolimus-eluting stent

Lisette Okkels Jensen, Lars Jakobsen, Ashkan Eftekhari, Julia Ellert-Gregersen, Nicolaj Brejnholt Støttrup, Thomas Engstrøm, Johnny Kahlert, Philip Freeman, Karsten Tange Veien, Rebekka Vibjerg Jensen, Jens Flensted Lassen, Anders Junker und 1 weitere

EuroIntervention · 2025

DOI: 10.4244/eij-d-24-00586 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift EuroIntervention, 2025. Verfasst von Lisette Okkels Jensen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Odense University Hospital, Odense, Denmark. Hauptthemen laut MEDLINE: Drug-Eluting Stents, Sirolimus, Percutaneous Coronary Intervention, Absorbable Implants. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The biolimus A9-coated polymer-free stent was not non-inferior for target lesion failure (TLF) when compared with an ultrathin-strut biodegradable-polymer sirolimus-eluting stent within 1 year in the Randomized Comparison of a Polymer-Free Biolimus-eluting BIOFREEDOM Stent With a Biodegradable-Polymer Sirolimus-eluting ORSIRO Stent in Patients Treated With Percutaneous Coronary Intervention (SORT OUT IX) trial. AIMS: We aimed to assess the 5-year outcomes of the drug-coated polymer-free biolimus-eluting stent versus an ultrathin-strut biodegradable-polymer sirolimus-eluting stent. METHODS: The SORT OUT IX trial was a registry-based, randomised, all-comer population trial. The primary endpoint, TLF, was defined as the composite of cardiac death, myocardial infarction (MI) not related to any segment other than the target lesion, or target lesion revascularisation (TLR) within 1 year. Follow-up was extended to 5 years. RESULTS: A total of 3,151 patients were randomly assigned to receive either the polymer-free biolimus-coated stent (1,572 patients [1,966 lesions]) or the ultrathin-strut biodegradable-polymer sirolimus-eluting stent (1,579 patients [1,985 lesions]). Only 0.3% of participants were lost to follow-up, and all of those were due to emigration. At 5 years, TLF was 14.1% in the polymer-free biolimus-coated stent group and 12.0% in the ultrathin-strut biodegradable-polymer sirolimus-eluting stent group (rate ratio [RR] 1.19, 95% confidence interval [CI]: 0.97-1.44). Cardiac death, MI and definite stent thrombosis did not differ between the two groups. Clinically driven TLR was 7.6% versus 5.0% (RR 1.56, 95% CI: 1.17-2.07) and was higher in the polymer-free biolimus-coated stent group at 5 years, attributable to a higher risk of TLR within the first year. CONCLUSIONS: Five-year TLF did not differ significantly between the drug-coated biolimus-eluting stent group and the ultrathin-strut biodegradable-polymer stent group, but the risk of TLR was higher in the drug-coated biolimus-eluting stent group.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug-Eluting StentsSirolimusPercutaneous Coronary InterventionAbsorbable ImplantsCoronary Artery DiseaseHumansMaleFemaleAgedMiddle AgedTreatment OutcomePolymersMyocardial InfarctionProsthesis Design

Substanzen

SirolimusumirolimusPolymers

Autor:innen und Institutionen

  • Department of Cardiology, Odense University Hospital, Odense, Denmark.
  • Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark.
  • Department of Cardiology, Rigshospitalet, Copenhagen, Denmark.
  • Department of Clinical Epidemiology, Aarhus University, Aarhus, Denmark.

Zitieren

APA

Jensen, L. O., Jakobsen, L., Eftekhari, A., Ellert-Gregersen, J., Støttrup, N. B., Engstrøm, T., Kahlert, J., Freeman, P., Veien, K. T., Jensen, R. V., Lassen, J. F., Junker, A., & Christiansen, E. H. (2025). Five-year outcomes of a drug-coated polymer-free biolimus-eluting stent versus an ultrathin-strut biodegradable-polymer sirolimus-eluting stent. EuroIntervention. https://doi.org/10.4244/eij-d-24-00586

Vancouver

Jensen LO, Jakobsen L, Eftekhari A, Ellert-Gregersen J, Støttrup NB, Engstrøm T, et al. Five-year outcomes of a drug-coated polymer-free biolimus-eluting stent versus an ultrathin-strut biodegradable-polymer sirolimus-eluting stent. EuroIntervention. 2025. doi:10.4244/eij-d-24-00586

BibTeX
@article{Jensen2025,
  author = {Jensen, Lisette Okkels and Jakobsen, Lars and Eftekhari, Ashkan and Ellert-Gregersen, Julia and Støttrup, Nicolaj Brejnholt and Engstrøm, Thomas and Kahlert, Johnny and Freeman, Philip and Veien, Karsten Tange and Jensen, Rebekka Vibjerg and Lassen, Jens Flensted and Junker, Anders and Christiansen, Evald Høj},
  title = {Five-year outcomes of a drug-coated polymer-free biolimus-eluting stent versus an ultrathin-strut biodegradable-polymer sirolimus-eluting stent},
  journal = {EuroIntervention},
  year = {2025},
  doi = {10.4244/eij-d-24-00586}
}
Kostenlos starten →